We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Clinical Diagnostic Tests to Be Developed

By Labmedica staff writers
Posted on 19 May 2008
Print article
New clinical diagnostic tests are to be developed in the areas of companion diagnostics, metabolic syndrome, oncology, and diabetes.

Companion diagnostics are tests designed to identify the suitability of a particular drug therapy for individual patients. The tests are used in personalized medicine to improve safety and efficacy of therapeutic drugs and in some cases, to help determine optimal dosing for individual patients. Metabolic syndrome is characterized by a person having multiple risk factors such as high blood pressure, heart disease, obesity, and diabetes. It is estimated that more than 50 million people are affected by this syndrome in the United States alone.

Diabetes is a chronic disease currently affecting more than 180 million people worldwide and is likely to more than double by 2030. Early detection and treatment of diabetes may enable a patient to better maintain his or her lifestyle. The early detection of cancer is important as it may lead to higher survival rates. One in eight deaths worldwide is due to cancer, and in 2007, there were more than 12 million estimated new cancer cases worldwide.

Siemens Healthcare (Deerfield, IL, USA) and Laboratory Corporation of America Holdings (LabCorp; Burlington, NC, USA) have entered a non-exclusive agreement to discuss the development of the new clinical diagnostic tests. Under the agreement, initial discussions will focus on developing new tests that could make the biggest impact to patient care.

Siemens Healthcare is a fully integrated diagnostics company, bringing together imaging and lab diagnostics, therapy, and healthcare information-technology systems, supplemented by consulting and support services. Siemens Healthcare provides solutions across the entire continuum of care--from prevention and early detection, to diagnosis, therapy, and care.

Laboratory Corporation of America commercializes new diagnostic technologies offering clinical assays ranging from routine blood analyses to HIV and genomic testing. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies.


Related Links:
Siemens Healthcare
Laboratory Corporation of America
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Automated Blood Typing System
IH-500 NEXT
New
Vitamin B12 Test
CHORUS CLIA VIT B12
New
Auto-Chemistry Analyzer
CS-1200

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.